Transactions
6
Insider / BridgeBio Oncology Therapeutics, Inc.
Cobo Marc
Principal Accounting Officer at BridgeBio Oncology Therapeutics, Inc.
- Ticker
- BBOT
- First filing on record
- July 6, 2026
- Latest trade on record
- October 21, 2026
- SEC filings
- EDGAR ↗
Cobo Marc, Principal Accounting Officer at BridgeBio Oncology Therapeutics, Inc., has disclosed 6 transactions in BBOT since July 6, 2026: 0 purchases (0 open-market buys) and 4 sales, worth about $3,136 at the reported prices. The latest was filed October 23, 2026, 2 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
4
Avg. disclosure lag
3.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Cobo Marc made no purchases and 4 sales worth $3K, plus 2 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Cobo Marc has traded 1 stock on record; the largest by dollars is BBOT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| F | Shares withheld for tax | 4 | 657 | $3,136 |
| A | Grant or award | 2 | 52,738 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 6 | 0 | 4 · $3,136 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BBOT | Sell F | October 21, 2026 | October 23, 2026 | 2d | 203 | $3 | $544 | Form 4 ↗ | ||
| BBOT | Sell F | October 1, 2026 | October 5, 2026 | 4d | 126 | $4 | $496 | Form 4 ↗ | ||
| BBOT | Other A | September 10, 2026 | September 14, 2026 | 4d | 43,700 | — | — | derivative | Form 4 ↗ | |
| BBOT | Sell F | September 10, 2026 | September 14, 2026 | 4d | 203 | $6 | $1,121 | Form 4 ↗ | ||
| BBOT | Other A | September 10, 2026 | September 14, 2026 | 4d | 9,038 | — | — | Form 4 ↗ | ||
| BBOT | Sell F | July 1, 2026 | July 6, 2026 | 5d | 125 | $8 | $975 | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 23, 2026 | Form 4 | 0001193125-26-430449 | 1 | published | EDGAR ↗ |
| October 5, 2026 | Form 4 | 0001193125-26-414135 | 1 | published | EDGAR ↗ |
| September 14, 2026 | Form 4 | 0001193125-26-390624 | 3 | published | EDGAR ↗ |
| July 6, 2026 | Form 4 | 0001193125-26-296504 | 1 | published | EDGAR ↗ |
Other insiders at BridgeBio Oncology Therapeutics, Inc.
- Kumar Neil Chief Executive Officer 158 rows
- MCCORMICK FRANK Director 9 rows
- Beltran Pedro Chief Scientific Officer 6 rows
- Ben Yong Chief Med & Dev Officer 5 rows
- Chen Bihua Director 5 rows
- Bauer Jake Director 3 rows
- Elmelech Idan COO & Principal Financial Ofcr 3 rows
- Mehra Uneek Chief Financial Officer 3 rows
- Wallace Eli M. Chief Executive Officer 3 rows
- Lebowitz Peter F Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: BridgeBio Oncology Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 6 | July 6, 2026 | October 23, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.